STX11抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 30 μg, Lane: Mouse liver tissue, Primary antibody: P04041(IGFBP1 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04041(IGFBP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04041(IGFBP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The STX11 antibody targets Syntaxin 11. a protein encoded by the *STX11* gene, which belongs to the Syntaxin family of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. SNARE proteins mediate intracellular membrane fusion events critical for vesicular trafficking, secretion, and autophagy. STX11 lacks a transmembrane domain but localizes to membranes via interactions with other SNAREs, playing a role in endosomal and lysosomal pathways. It is highly expressed in immune cells, particularly cytotoxic T cells and natural killer (NK) cells, where it regulates granule exocytosis and immune synapse formation.

Mutations in *STX11* are linked to familial hemophagocytic lymphohistiocytosis type 4 (FHL4), a rare autosomal recessive disorder characterized by immune dysregulation, hyperinflammation, and defective cytotoxic cell function. STX11 antibodies are widely used in research to study its expression, localization, and interactions in immune cells, aiding in understanding FHL4 pathogenesis. They are also employed in diagnostics to detect STX11 protein levels in patient samples.

Commercially available STX11 antibodies are typically developed in rabbits or mice using recombinant protein fragments or synthetic peptides. Applications include Western blotting, immunofluorescence, flow cytometry, and immunohistochemistry. Researchers also use these antibodies to explore STX11’s role in cancer, as abnormal expression has been observed in certain malignancies. Validation via knockout cell lines or siRNA knockdown is recommended due to potential cross-reactivity with other Syntaxin family members.